247 related articles for article (PubMed ID: 26166734)
1. IncobotulinumtoxinA for Migraine: A Retrospective Case Series.
Kazerooni R; Lim J; Ashley Blake P; Lessig S
Clin Ther; 2015 Aug; 37(8):1860-4. PubMed ID: 26166734
[TBL] [Abstract][Full Text] [Related]
2. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
Hepp Z; Rosen NL; Gillard PG; Varon SF; Mathew N; Dodick DW
Cephalalgia; 2016 Aug; 36(9):862-74. PubMed ID: 26692400
[TBL] [Abstract][Full Text] [Related]
4. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN
Ion I; Renard D; Le Floch A; De Verdal M; Bouly S; Wacongne A; Lozza A; Castelnovo G
Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29857565
[TBL] [Abstract][Full Text] [Related]
5. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
[TBL] [Abstract][Full Text] [Related]
6. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
8. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU
Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228
[TBL] [Abstract][Full Text] [Related]
9. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
10. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
[TBL] [Abstract][Full Text] [Related]
11. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
Frampton JE
Drugs; 2012 Apr; 72(6):825-45. PubMed ID: 22468643
[TBL] [Abstract][Full Text] [Related]
12. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
[TBL] [Abstract][Full Text] [Related]
13. [Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].
Bernhard MK; Bertsche A; Syrbe S; Weise S; Merkenschlager A
Fortschr Neurol Psychiatr; 2014 Jan; 82(1):39-42. PubMed ID: 24446117
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
Blumenfeld A
Headache; 2003 Sep; 43(8):853-60. PubMed ID: 12940806
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.
Jackson JL; Kuriyama A; Hayashino Y
JAMA; 2012 Apr; 307(16):1736-45. PubMed ID: 22535858
[TBL] [Abstract][Full Text] [Related]
16. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm.
Chundury RV; Couch SM; Holds JB
Ophthalmic Plast Reconstr Surg; 2013; 29(3):205-7. PubMed ID: 23552607
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
18. Effect of 3 Commercially Available Botulinum Toxin Neuromodulators on Facial Synkinesis: A Randomized Clinical Trial.
Thomas AJ; Larson MO; Braden S; Cannon RB; Ward PD
JAMA Facial Plast Surg; 2018 Mar; 20(2):141-147. PubMed ID: 28973094
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study.
Zidan A; Roe C; Burke D; Mejico L
J Clin Neurosci; 2019 Nov; 69():237-240. PubMed ID: 31327585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
